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Introduction: Cardiotoxicity is an important complication of several cancer therapeutic agents. The 
spectrum of cardiovascular complications of cancer therapy is wide and includes left ventricular (LV) 
dysfunction, congestive heart failure (CHF), coronary vasospasm, angina, myocardial infarction, ar-
rhythmias, systemic hypertension, pericardial effusion, pulmonary fibrosis and pulmonary hyper-
tension.1,2 Several anticancer agents, such as anthracyclines, trastuzumab/pertuzumab (monoclonal 
antibodies), cyclophosphamide, 5-fluorouracil, angiogenesis inhibitors and tyrosine kinase inhibitors 
(TKIs) are associated with an increase in the risk of cardiovascular morbidity and mortality.
Case report: 47-year-old woman with diagnosed breast cancer (pathohistological diagnosis: invasive 
carcinoma), started with neoadjuvant chemotherapy (doxorubicin and cyclophosphamide). From 
earlier in the patient known chronic kidney disease with stable renal function. Prior to treatment, 
echocardiography was performed and determine the preserved systolic function of LVEF 62%, GLPS 
Avg -13,8%. After two cycles of chemotherapy, the deterioration of renal function was monitored, and 
treatment with taxane (paclitaxel) was started, cyclophosphamide was excluded. Concomitantly with 
the taxane the patient was treated with double anti-HER therapy (trastuzumab + pertuzumab). After 6 
months, the patient has an intolerance to physical exertion, bilateral pleural effusions present on lung 
X-ray, and laboratory analysis shows NT-proBNP >30000 ng/L with further exacerbation of chronic 
renal injury (terminal stage). Control echocardiography showed significantly reduced systolic func-
tion LVEF 25% globally reduced contractility, with dilatation of the left heart cavities, GLPS Avg -5,6%.
Conclusion: The development of newer, more potent and targeted chemotherapeutic agents has im-
proved the outcome of patients with cancers, but a cardiotoxic effect should be considered, especially 
if more than one cardiotoxic drug is administered.3,4 It’s also important to individually assess the pos-
sible cardiac consequences in each patient with regular echocardiographic monitoring. Timely de-
termination of the cardiotoxic effect certainly changes the course of the disease and affects the final 
outcome.
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